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Abstract
Background:  Chronic inflammation appears to play a role in the pathogenesis of vascular dementia. Given the
association between Chlamydia pneumoniae and stroke, the possibility exists that previous exposure to C. pneumoniae may
play a role in vascular dementia. The objective of this study was to determine if there was an association between
serological evidence of C. pneumoniae infection or inflammatory markers with vascular dementia.
Methods: 28 case-patients with vascular dementia at a geriatric clinic and 24 caregiver-controls were tested for C.
pneumoniae IgG and IgA antibodies. The association between vascular dementia and C. pneumoniae titres as well as
inflammatory markers was estimated by using both conditional logistic regression and stratified logistic regression.
Results: When matched cases were compared to controls, there was no significant difference in elevated C. pneumoniae
specific IgG antibodies (titre ≥ 1:32), odds ratio [OR] 1.3 (95% confidence intervals [CI] 0.3 to 6.0), p = 0.71, or in
elevated C. pneumoniae specific IgA antibodies (titre ≥ 1:16), OR 2.0 (95%CI 0.5 to 8.0), p = 0.33 indicative of past or
persistent C. pneumoniae infection. Similarly, no difference in high IgG or IgA antibody levels (IgG titre ≥ 1:512 or IgA
titre ≥ 1:64) between the two groups, indicative of recent C. pneumoniae infection, was found, OR 0.4 (95%CI 0.1 to 2.1),
p = 0.27. For C-reactive protein (CRP), the mean difference between 18 matched pairs (case – control) was – 3.33 mg/
L. There was no significant difference between cases and controls when comparing log transformed values, OR 0.03
(95%CI 0.00 to 2.89), p = 0.13 or comparing CRP values above or below the median, OR 0.8 (95%CI 0.2 to 3.4), p =
0.71. For fibrinogen, the mean difference between pairs (case – control) was -0.07 g/L. There was no statistical difference
between cases and controls when comparing log transformed values, OR 0.6 (95%CI 0.0 to 31.2), p = 0.79 or between
fibrinogen values above and below the median, OR = 0.5 (95%CI 0.1 to 2.0), p = 0.50.
Conclusion: We found no evidence for a significant association between C. pneumoniae infection, inflammatory markers
such as CRP and fibrinogen, and vascular dementia.
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Background
Vascular dementia is characterized by a loss of cognitive
function and social adaptive functions in individuals with
cerebrovascular disease [1,2]. Vascular dementia is the
second most common cause of dementia and accounts for
10% to 15% of all cases [3]. The clinical presentation of
this illness is variable, depending on the site and extent of
the lesion or infarct [2]. The pathogenesis of vascular
dementia has not been well defined [1,3]. Chronic
inflammation and cytokine dysregulation may play a role
[4] similar to that seen in Alzheimer's disease [5].
Recent data from serological and PCR studies support an
association between Chlamydia pneumoniae and cerebrov-
ascular disease. C. pneumoniae has been associated with
stroke, transient cerebral ischemia, and atherosclerosis in
the middle cerebral artery in both prospective and case-
control studies [6-12]. Since stroke is an important precur-
sor to vascular dementia, these data raise the possibility
that C. pneumoniae infection may also be a risk factor for
vascular dementia. To our knowledge, this potential rela-
tionship has not previously been assessed. We conducted
a pilot case-control study to determine an association
between serological evidence of C. pneumoniae infection
and vascular dementia. We also sought to determine if the
inflammatory markers, C-reactive protein (CRP) and
fibrinogen were associated with this illness.
Methods
Study design
Patients with vascular dementia were enrolled from the
Geriatric Clinic at Henderson Hospital, an outpatient
clinic affiliated with a tertiary hospital in Hamilton,
Ontario. The diagnosis of vascular dementia for partici-
pants enrolled was determined in accordance with criteria
established by the Neuroepidemiology Branch of the
National Institute of Neurological Disorders and Stroke
and Association Internationale pour la Recherche et
l'Enseignement en Neurosciences (NINDS-AIREN) Inter-
national workshop [13]. This includes both physical and
imaging evidence of strokes, and a temporal relationship
between stroke and dementia [3]. Case-patients meeting
any of the following criteria were excluded: 1) cognitive
impairment due to acute cerebral trauma, hypoxic cere-
bral damage post cardiac arrest, vitamin deficiency states,
central nervous system infection, cerebral neoplasia, sig-
nificant endocrine or metabolic disease, mental retarda-
tion; 2) stroke within the last 6 weeks; 3) patients known,
in the past 3 months, to have taken a 7 day or more course
of antibiotics with activity against C. pneumoniae (erythro-
mycin, clarithromycin, azithromycin, levofloxacin, trova-
floxacin, doxycycline, or tetracycline).
The controls for this study were chosen from a list of all
caregivers who attended the geriatric clinic at the time of
the study, regardless of the diagnosis of their spouse or
family member. For each case, one caregiver matched for
age (within five years) and sex was selected. Caregivers
were excluded if they had a diagnosis that included any of
the following: dementia, stroke, or cognitive impairment
as determined by a Standardized Mini-Mental Status
Examination score of < 27 [14]. Enrolment was from July
1999 to October 2001. All eligible cases and controls who
attended the clinic during the study period were
approached for consent to participate in the study. Demo-
graphic data (age, sex), medical history, and smoking his-
tory were collected as well as blood samples for C.
pneumoniae IgG and IgA antibodies, CRP, and fibrinogen.
This study was approved by the research ethics board at
McMaster University. Signed consent was obtained for all
participants (proxy consent was utilized for participants
considered decisionally impaired).
Laboratory methods
For C. pneumoniae IgG and IgA antibody detection, all sera
were titrated at two-fold dilutions from 1:16 to endpoint.
Samples were analyzed by microimmunofluorescence
(MIF), using a 16 hour incubation of serum and substrate
at 4–8°C with the same batch of C. pneumoniae IgG/IgM
MIF slides (LabSystems OY, Helsinki) (23). To prevent
IgG interference, sera used for IgA detection were first
treated with goat anti-human IgG antibodies (GullSorb;
Gull Laboratories, Salt Lake City, UT, USA). CRP was
measured using a high sensitivity automated rate neph-
elometric immunoassay (Dade Behring high-sensitivity
CRP, BNII Nephelometer System, Marburc, DE). Fibrino-
gen was assayed using an automated STA fibrinogen assay
(von Clauss method) on a Roche/Stago (Diagnostica
Stago SA).
Analysis
The presence of elevated antibody levels, indicative of past
or persistent C. pneumoniae infection, was defined as an
IgG titre of 1:32 or greater and IgA of 1:16 or greater
[15,16]. High antibody titres to C. pneumoniae, suggesting
a more recent infection, was defined by IgG titres of 1:512
or greater or IgA titres of 1:64 or greater [16]. Because a
skewed distribution was anticipated and a linear relation-
ship with risk was not expected, CRP and fibrinogen were
analyzed in two ways: using a log transformation of the
values and dichotomizing at the median.
The association between vascular dementia and C. pneu-
moniae  titres and inflammatory markers was estimated
using a matched analysis. Conditional logistic regression
analyses were performed for antibody levels, dichot-
omized and log transformed CRP, as well as dichot-
omized and log transformed fibrinogen.BMC Neurology 2004, 4:15 http://www.biomedcentral.com/1471-2377/4/15
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A stratified logistic regression analysis was also conducted
for C. pneumoniae titres and inflammatory markers (both
log transformed and dichotomized at the median), strati-
fying by age and sex (the following age strata were used: ≤
70 years, 71–80 years, 81–90 years). All analyses for C.
pneumoniae  titres and inflammatory markers were also
performed with adjustment for current smoking status.
Data analyses were performed with SPSS version 10 or
Egret for Windows version 2.0.3.
The original protocol involved two concurrent case-con-
trol studies: one including 30 vascular dementia patients
and 30 controls and the other with 30 Alzheimer disease
patients and 30 controls. The analysis was to include the
additional 30 Alzheimer disease controls in the vascular
dementia analysis (giving a 1:2 case:control ratio). Assum-
ing that one third of controls would have elevated C. pneu-
moniae  titres, for an alpha of 0.05 and 80% power,
matching 30 cases to 60 controls would allow for detec-
tion of an odds ratio of 3.8 or higher. As the study pro-
ceeded, it became apparent that enrolling the Alzheimer's
patients was not feasible. We decided then to limit the
analysis to a 1:1 case:control ratio focusing on 30 patients
with vascular dementia.
Results
Participants
A total of 28 case-patients were enrolled: mean age 76.2
years (minimum to maximum: 56 to 90 years); 18 (64%)
were male. Nine of the 28 cases had at least one comor-
bidity (including angina, coronary heart disease, vascular
disease, liver disease and renal disease); 1 case had 3 or
more comorbidities. Thirteen of the cases were current
smokers.
Twenty of the 28 cases could be matched to caregiver-con-
trols, for a total of 20 case-control pairs. Of these 20 car-
egiver-controls, 16 were unrelated to a case, and four were
spouses of a case. However, none of these four were
matched to their spouse. Four additional caregiver-con-
trols were selected for the unmatched analyses, so that
data on a total of 24 caregiver-controls was obtained.
Where there was incomplete data on antibody or inflam-
matory marker levels, those pairs were excluded from
matched analyses. Incomplete information on cases and
controls occurred when individuals consented to partici-
pate in the study and provided medical information but
did not attend the out-patient clinic for the required
blood collection. All individuals with complete data were
included in the unmatched analyses.
C. pneumoniae serology
Univariate analysis of C. pneumoniae specific IgG antibod-
ies showed no statistically significant difference in ele-
vated antibody levels between matched case-patients and
controls, odds ratio [OR] = 1.3 (95% confidence intervals
[CI] 0.3 to 6.0), p = 0.71. When pairs were broken and
stratified analyses were performed the difference was not
statistically significant, OR = 1.8 (95%CI 0.4 to 8.3), p =
0.46. The analysis was also performed with adjustment for
participants' current smoking status, OR = 1.8 (95%CI 0.2
to 12.2), p = 0.57 (see Table 1).
Similarly, no statistically significant difference between
elevated C. pneumoniae specific IgA antibodies was found
between matched pairs, OR = 2.0 (95%CI 0.5 to 8.0), p =
0.33. The stratified analysis produced slightly higher odds
ratio estimates, although not statistically significant. For
the unadjusted analysis, OR = 2.8 (95%CI 0.7 to 10.4), p
= 0.13 and for the adjusted analysis, OR = 2.7 (95%CI 0.5
to 14.2), p = 0.24 (see Table 1).
There was also no statistical difference in high antibody
levels between matched pairs, OR = 0.4 (95%CI 0.1 to
2.1), p = 0.27 or in the stratified analysis, OR = 0.6
(95%CI 0.2 to 2.0), p = 0.40 for the unadjusted analysis
and OR = 0.5 (95%CI 0.1 to 2.5), p = 0.41 for the adjusted
analysis (see Table 1).
Inflammatory markers
A matched analysis of CRP performed on 18 of the 20
matched pairs (all pairs with complete data) revealed no
significant difference between log-transformed values, OR
of 0.03 (95%CI 0.00 to 2.89), p = 0.13. Similarly, there
was no difference comparing matched cases and controls
with CRP values above or below the median, OR = 0.8
(95%CI 0.2 to 3.4), p = 0.71. In the stratified analysis
(Table 2), the log transformed CRP variable and the CRP
variable dichotomized at the median were not statistically
significant in both the unadjusted (OR = 0.5 (95%CI 0.1
to 3.6), p = 0.50 and OR = 2.2 (95%CI 0.7 to 7.2), p =
Table 1: Comparison of analyses used to assess for associations of 
C. pneumoniae specific serology and vascular dementia
Variable Conditional Stratified* Adjusted**
OR p n1 OR p n2 OR p n2
IgG response 1.5 0.66 15 1.8 0.46 48 1.7 0.50 48
IgA response 1.7 0.48 15 2.8 0.13 48 3.0 0.11 48
High titre 
response
0.4 0.27 15 0.6 0.40 48 0.5 0.34 48
1 Number of pairs included in the analysis
2 Number of individuals included in the analysis
* Stratified on age (≤ 70 years, 71–80 years, 81–90 years) and gender
**Stratified analysis with adjustment for current smoking statusBMC Neurology 2004, 4:15 http://www.biomedcentral.com/1471-2377/4/15
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0.20, respectively) and the adjusted analysis (OR = 0.4
(95%CI 0.04 to 4.7), p = 0.49 and OR = 1.4 (95%CI 0.3
to 6.3), p = 0.64, respectively).
A matched analysis of fibrinogen performed on the same
18 pairs revealed no significant difference between the
log-transformed values of the two groups, OR = 0.6
(95%CI 0.0 to 31.2), p = 0.79. Similarly, there was no dif-
ference when comparing the pairs on fibrinogen values
above and below the median, OR = 0.5 (95%CI 0.1 to
2.0), p = 0.33. In the stratified analysis (Table 2), the log
transformed fibrinogen variable and the fibrinogen varia-
ble dichotomized at the median were not statistically sig-
nificant in both the unadjusted (OR = 0.8 (95%CI 0.0 to
71.6), p = 0.92 and OR = 0.6 (95%CI 0.2 to 2.0), p = 0.38,
respectively) and the adjusted analysis (OR = 0.1 (95%CI
0.0 to 73.9), p = 0.43 and OR = 0.3 (95%CI 0.1 to 1.6), p
= 0.17, respectively).
Discussion
In this case-control study, we found no significant associ-
ation between elevated or high C. pneumoniae specific IgG
or IgA antibodies and vascular dementia. To our knowl-
edge, this is the first epidemiologic study to test for an
association between vascular dementia and infection with
C. pneumoniae.
We conducted this study on the basis of evidence linking
C. pneumoniae to cardiovascular disease and stroke. There
is an extensive literature supporting an association
between  C. pneumoniae and atherosclerosis [17-19].
Although the majority of these studies initially focused on
coronary heart disease more recent evidence also supports
an association with stroke [6-12,20]. However, the clinical
importance of this association is uncertain.
Although no significant associations were noted, the rela-
tively small sample size and the odds ratio estimates for
elevated IgA and IgG antibodies do not definitively rule
out an association. In fact, we powered this study to detect
a minimally important association between antibodies
and vascular dementia of 3.8. Given that the odds ratio
95% confidence interval of IgG is from 0.3 to 6.0, and 0.5
to 8.0 for IgA, our data do not rule out clinically important
associations. The point estimates for elevated IgA and IgG
antibodies (2.0 and 1.3, respectively) are similar to the
recent meta-analysis odds ratio estimates for coronary
heart disease of 1.25 (95% CI 1.03 to 1.53) and 1.15
(95% CI 0.97 to 1.36), respectively [21,22]. In both cases
the odds ratio estimate for IgA titres is slightly higher than
IgG titres, but not statistically different. The meaning of
this difference is uncertain. Danesh et al [21] suggest that
these differences are likely due to chance, selection biases,
or selective emphasis on particular reports. In contrast,
other studies have suggested that IgA titres are more
strongly associated with disease outcomes because they
are a better indicator of chronic C. pneumoniae infection
[23,15,10].
Vascular dementia is the second most common cause of
dementia, second only to Alzheimer's disease. It was pre-
viously believed that most cases of dementia were the out-
come of one of these two distinct diseases. However, the
clear division between them has recently been challenged.
It is now widely believed that vascular risk factors are also
associated with Alzheimer's disease and Alzheimer's and
vascular dementia may share many common clinical and
pathological characteristics [3,24-26]. A number of stud-
ies have examined the association between Alzheimer's
disease and C. pneumoniae infection. In 1998 Balin et al
[27] found an extremely high association between the
presence of C. pneumoniae in post-mortem brain samples
and late-onset Alzheimer's disease. However, more recent
studies have not repeated these findings [28-31]. A recent
randomized controlled clinical trial [16], based on the
hypothesis that chronic C. pneumoniae infection contrib-
utes to Alzheimer's disease, found an improved long-term
cognitive state in patients with mild to moderate Alzhe-
imer's disease who had been treated with doxycycline and
rifampin. However, the serological data did not suggest
that this clinical effect was due to treatment of chronic C.
pneumoniae infection. One study has looked for C. pneu-
moniae in brain samples of vascular dementia patients.
This study, like the later AD studies, did not identify C.
pneumoniae in any of the brain samples [32]. These results
suggest that the presence of C. pneumoniae in the brains is
not strongly associated with late-onset Alzheimer's dis-
ease or vascular dementia.
Inflammatory responses are also known to be associated
with cardiovascular disease and have recently been impli-
cated in dementia [33]. Elevated levels of serum C-reactive
protein (CRP), a non-specific marker of inflammation,
Table 2: Comparison of analyses used to assess for associations of 
inflammatory markers and vascular dementia
Variable Conditional Stratified* Adjusted**
OR p n1 OR p n2 OR p n2
LogCRP 0.0 0.13 18 0.5 0.50 49 0.5 0.52 49
CRP 0.8 0.71 18 2.2 0.20 49 2.2 0.19 49
LogFibrinogen 0.6 0.79 18 0.8 0.92 49 0.6 0.83 49
Fibrinogen 0.5 0.33 18 0.6 0.38 49 0.5 0.32 49
1 Number of pairs included in the analysis
2 Number of individuals included in the analysis
* Stratified on age (≤ 70 years, 71–80 years, 81–90 years) and gender
**Stratified analysis with adjustment for current smoking statusBMC Neurology 2004, 4:15 http://www.biomedcentral.com/1471-2377/4/15
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predict cardiovascular disease [34] and dementia [33],
and have been associated with stroke patients [35].
Recently, an association between inflammatory markers
alpha 1-antichymotrypsin, interleukin 6, and, to a lesser
extent, C-reactive protein were associated with an
increased risk of dementia [36]. In this study we did not
find a significant difference in CRP levels between the
cases and controls. This most likely was due to the limited
power in the study and the limitations of measuring
serum CRP. Although CRP was originally thought to be
produced almost exclusively by hepatocytes, CRP is now
known to be synthesized in brain cells and upregulated in
Alzheimer tissue [37,38]. Consequently, localized
increases in CRP may be associated with vascular demen-
tia but not detected with serum measurements.
We found no significant association between increased
fibrinogen levels and vascular dementia. Abnormalities of
haemostasis are thought to be important in the pathogen-
esis of cardiovascular disease, ischaemic stroke, and vascu-
lar dementia. Within the pathways of coagulation and
fibrinolysis, fibrinogen represents an important marker.
Elevated levels of fibrinogen are associated with increased
risks of cardiovascular disease and ischaemic stroke
[39,40] but the results are less conclusive for vascular
dementia [41,42]. Lowe and Haverkate [43] believe that
because vascular dementia is only one phenotype of the
systemic atherothrombosis disease, associations between
haemostatic variables and any given phenotype should be
interpreted with caution. To show a specific association
with a single phenotype, a study would need an extremely
large sample size to overcome the overlap in phenotypes
and risk factors seen in atherothrombosis.
We acknowledge several limitations of this study. Because
of the relatively small sample size, the analyses were
adjusted for only a small number of potentially important
covariates and the analysis of CRP and fibrinogen was
restricted to above and below the median (while quartiles
would have been more sensitive). To adjust for variables
that were not used as matching criteria and to maximize
the data collected a stratified analysis was also done. The
additional stratified analysis adjusted for current smoking
status. We adjusted for smoking status because there is a
known strong association between smoking and C. pneu-
moniae titres; and between smoking and vascular demen-
tia [44]. However, it may also be important to adjust for
additional factors that may affect inflammatory markers.
We also acknowledge that C. pneumoniae serology is an
imperfect test of C. pneumoniae exposure and chronic
infection. First, the high prevalence of C. pneumoniae
exposure makes it difficult to detect true serological differ-
ences between cases and controls. Second, it is unclear
what the appropriate serological cut-offs should be for
identifying exposure versus chronic infection or recent
infections. As a result, different groups have used different
criteria making comparisons across studies more difficult.
However, the importance of this inconsistency is unclear.
In the meta-analysis reported by Danesh et al [21] no sig-
nificant heterogeneity was found among the studies even
though four different cut-off titres were used to determine
seropositivity in the microimmunofluorescence assays.
An alternative test, that may prove to be more reliable,
involves the detection of C. pneumoniae DNA in peripheral
blood mononuclear cells [45]. Another potential limita-
tion is the choice of controls; because C. pneumoniae is
infectious an increased exposure in the caregivers could
potentially mask a statistically significant association
between the patients and controls. There is also evidence
that caregivers, because of stress, may have altered
immune systems [46] which could interfere with their
generation of antibodies and inflammatory markers [47-
49].
Conclusions
In summary, a case-control study of vascular dementia
patients suggests that there is no significant association
between C. pneumoniae antibodies and vascular dementia.
We found no evidence for a significant association
between systemic inflammatory markers and vascular
dementia. While this study can rule out a strong associa-
tion, larger studies are necessary to determine if a weak
association exists.
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